Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Asieris Collaborates with ReviR to Discover RNA Candidates for Genitourinary Tumors

publication date: Feb 8, 2023

Shanghai Asieris Pharma formed a research collaboration with San Francisco’s ReviR Therapeutics to develop novel therapies for genitourinary (GU) tumors. The companies will use ReviR’s proprietary RNA-targeted technologies to discover and develop candidates for multiple oncology targets. ReviR combines computational and high throughput drug discovery technologies for drug discovery. Asieris will use ReviR's innovative RNA modulation technologies, named BindeR and SpliceR, to identify and develop the candidates. A genitourinary cancer company, Asieris will have an option to license any candidates. More details....

Stock Symbol: (SHA: 688176)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital